Literature DB >> 8578508

Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists.

L A Harker1, S R Hanson, A B Kelly.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8578508

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  4 in total

Review 1.  Future directions in thrombolysis.

Authors:  J T Willerson; P Zoldhelyi
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

2.  Factor Xa: simulation studies with an eye to inhibitor design.

Authors:  X Daura; E Haaksma; W F van Gunsteren
Journal:  J Comput Aided Mol Des       Date:  2000-08       Impact factor: 3.686

Review 3.  Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.

Authors:  Pancras C Wong; Donald J P Pinto; Donglu Zhang
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

Review 4.  Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation.

Authors:  Michael S Hanna; Puneet Mohan; Robert Knabb; Elora Gupta; Charles Frost; John H Lawrence
Journal:  Ann N Y Acad Sci       Date:  2014-11-05       Impact factor: 5.691

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.